X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11) 11
cardiac & cardiovascular systems (8) 8
clopidogrel (8) 8
female (8) 8
humans (8) 8
male (8) 8
stent thrombosis (8) 8
aged (7) 7
drug-eluting stents (7) 7
risk factors (7) 7
middle aged (6) 6
percutaneous coronary intervention - adverse effects (6) 6
thrombosis (6) 6
stent (5) 5
stents (5) 5
blood clot (4) 4
implantation (4) 4
implants (4) 4
myocardial infarction (4) 4
percutaneous coronary intervention (4) 4
platelet aggregation (4) 4
platelet function tests (4) 4
predictors (4) 4
registries (4) 4
stents - adverse effects (4) 4
time factors (4) 4
acute coronary syndrome (3) 3
aspirin (3) 3
bare-metal stents (3) 3
cardiac patients (3) 3
care and treatment (3) 3
coronary thrombosis - prevention & control (3) 3
incidence (3) 3
management (3) 3
medical research (3) 3
medicine, experimental (3) 3
neoatherosclerosis (3) 3
patients (3) 3
peripheral vascular disease (3) 3
platelet aggregation inhibitors - therapeutic use (3) 3
prasugrel (3) 3
purinergic p2y receptor antagonists - therapeutic use (3) 3
st elevation myocardial infarction - blood (3) 3
st elevation myocardial infarction - surgery (3) 3
transluminal angioplasty (3) 3
abridged index medicus (2) 2
adenosine - analogs & derivatives (2) 2
adenosine - therapeutic use (2) 2
antiplatelet therapy (2) 2
blood platelets (2) 2
blood platelets - drug effects (2) 2
cardiovascular diseases (2) 2
clinical-outcomes (2) 2
coronary heart disease (2) 2
coronary thrombosis - blood (2) 2
coronary thrombosis - diagnostic imaging (2) 2
coronary thrombosis - etiology (2) 2
coronary thrombosis - metabolism (2) 2
dual antiplatelet therapy (2) 2
elevation myocardial-infarction (2) 2
graft occlusion, vascular - epidemiology (2) 2
graft occlusion, vascular - prevention & control (2) 2
hematology (2) 2
imaging (2) 2
impact (2) 2
impaired bioavailability (2) 2
netherlands (2) 2
p2y (2) 2
prospective studies (2) 2
purinergic p2y receptor antagonists - adverse effects (2) 2
recurrence (2) 2
retrospective studies (2) 2
review article (2) 2
stroke (2) 2
surgical implants (2) 2
therapy (2) 2
thromboembolism (2) 2
ticagrelor (2) 2
ticlopidine - analogs & derivatives (2) 2
ticlopidine - therapeutic use (2) 2
trials (2) 2
10149 (1) 1
10153 (1) 1
acquisition (1) 1
acute coronary syndrome - drug therapy (1) 1
acute coronary syndrome - therapy (1) 1
acute coronary syndromes (1) 1
acute myocardial-infarction (1) 1
adenosine - adverse effects (1) 1
adenosine diphosphate - blood (1) 1
adult (1) 1
adverse events (1) 1
aged, 80 and over (1) 1
amplification (1) 1
antiplatelet agents (1) 1
arterial (1) 1
artery-disease (1) 1
article subject (1) 1
association (1) 1
atherosclerosis (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood Coagulation & Fibrinolysis, ISSN 0957-5235, 09/2019, Volume 30, Issue 6, pp. 263 - 269
High on-treatment platelet reactivity (HPR) on P2Y12-inhibitors in patients treated with dual antiplatelet therapy is strongly associated with adverse... 
Journal Article
Circulation, ISSN 0009-7322, 09/2017, Volume 136, Issue 11, pp. 1007 - 1021
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 09/2019, Volume 75, Issue 9, p. 1201
In a single-center prospective cohort study, patients with a high risk score were treated with prasugrel and patients with a low risk score with clopidogrel.... 
Stroke (Disease) | Transluminal angioplasty | Medical research | Care and treatment | Cytochrome P-450 | Medicine, Experimental | Clopidogrel | Risk factors
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2017, Volume 119, Issue 10, pp. 1500 - 1506
Abstract The recurrence rate of coronary stent thrombosis (ST) is high. ST patients often demonstrate high on-treatment platelet reactivity (HPR). It is... 
Cardiovascular | PERCUTANEOUS CORONARY INTERVENTION | IMPACT | CARDIAC & CARDIOVASCULAR SYSTEMS | CLOPIDOGREL | MANAGEMENT | BARE METAL STENTS | PRASUGREL | ELEVATION MYOCARDIAL-INFARCTION | DRUG-ELUTING STENTS | PLATELET REACTIVITY | CLINICAL-OUTCOMES | Recurrence | Follow-Up Studies | Death, Sudden, Cardiac - epidemiology | Humans | Middle Aged | Netherlands - epidemiology | Graft Occlusion, Vascular - prevention & control | Death, Sudden, Cardiac - prevention & control | Male | ST Elevation Myocardial Infarction - diagnosis | Incidence | ST Elevation Myocardial Infarction - blood | Dose-Response Relationship, Drug | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Electrocardiography | Female | Retrospective Studies | Graft Occlusion, Vascular - epidemiology | Survival Rate - trends | ST Elevation Myocardial Infarction - surgery | Stents - adverse effects | Percutaneous Coronary Intervention - adverse effects | Graft Occlusion, Vascular - blood | Heart | Relapse | Clinics | Thrombosis | Stent (Surgery) | Blood clot | Diseases | Myocardial infarction | Therapy | Surgical implants | Aspirin | Task forces | Medical imaging | Heart attacks | Mortality | Family medical history | Patients | Heart rate | Confidence intervals | Blood platelets | Implants | Clopidogrel | Death | Infarction | Acute coronary syndromes | Thromboembolism | Cardiology | Heart diseases | Stents
Journal Article
by Riegger, Julia and Byrne, Robert A and Joner, Michael and Chandraratne, Sue and Gershlick, Anthony H and Ten Berg, Jurrien M and Adriaenssens, Tom and Guagliumi, Giulio and Godschalk, Thea C and Neumann, Franz-Josef and Trenk, Dietmar and Feldman, Laurent J and Steg, Philippe Gabriel and Desmet, Walter and Alfonso, Fernando and Goodall, Alison H and Wojdyla, Roman and Dudek, Dariusz and Philippi, Vanessa and Opinaldo, Sheryl and Titova, Anna and Malik, Nikesh and Cotton, James and Jhagroe, Darshni A and Heestermans, Antonius A. C. M and Sinnaeve, Peter and Vermeersch, Paul and Valina, Christian and Schulz, Christian and Kastrati, Adnan and Massberg, Steffen and Buysschaert, Ian and Chausson, Mickaël and De Cock, Dries and Dens, Jo and Barbato, Emanuele and Gautier, Sandrine and Abergel, Helene and Jandrot-Perrus, Martine and Letourneur, Didier and Mangin, Pierre and Olivier, Veronique and Roques, Caroline and Gratz, Matthias and Kennerknecht, Elisabeth and Konrad, Ildiko and Koppara, Tobias and Ntziachristos, Vasilis and Rosenthal, Amir and Rzany, Alexander and Steigerwald, Kristin and Tada, Tomohiso and Vogelsang, Andreas and Xhepa, Erion and Bernelli, Chiara and Coccato, Micol and Komukai, Kenichi and Sirbu, Vasile and Kerch, Garry and Amoroso, Giovanni and Dewilde, Willem J.M and Heestermans, Antonius A. C. M and Wykrzykowska, Joanne J and Winkens, Mark H.M and Rzeszutko, Aukasz and Zasada, Wojciech and Cuesta, Javier and Medina, Miguel and Berry, Colin and Curzen, Nick and McEntegart, Margaret and Gerber, Robert and Hetherington, Simon and Hill, Jonathan and Kelly, Damian and Oldroyd, Keith and Routledge, Helen and Shannon, Joanne and Suresh, Venkatesan and Zahman, Azfar and Prevention Late Stent Thrombosis and Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators
European Heart Journal, ISSN 0195-668X, 05/2016, Volume 37, Issue 19, pp. 1538 - 1549
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 9/2019, Volume 75, Issue 9, pp. 1201 - 1210
The POPular Risk Score was developed for the selective intensification of P2Y12 inhibitor treatment with prasugrel instead of clopidogrel in patients... 
Prasugrel | Biomedicine | P2Y 12 inhibitor | Clopidogrel | Platelet aggregation | Percutaneous coronary intervention | Pharmacology/Toxicology | CYP2C19 | inhibitor | P2Y | Myocardial infarction | Cerebral infarction | Surgical implants | Stroke | Implantation | Risk analysis | Thrombosis | Patients | Bleeding | Risk factors | Amplification | Reduction | Inhibitors | Genotyping | Implants | Thromboembolism | Stents
Journal Article
Journal of Interventional Cardiology, ISSN 0896-4327, 10/2017, Volume 30, Issue 5, pp. 421 - 426
Objectives To estimate the incidence of stent thrombosis (ST) after early discontinuation of clopidogrel. Background Premature discontinuation of clopidogrel... 
stent thrombosis | acute coronary syndrome | antiplatelet therapy | Medical research | Medicine, Experimental | Coronary heart disease | Thrombosis | Risk factors | Blood clot | Stent (Surgery) | Clopidogrel | Risk groups | Stents | Implants
Journal Article
Seminars in Thrombosis and Hemostasis, ISSN 0094-6176, 06/2017, Volume 43, Issue 4, pp. 439 - 446
Journal Article
Cardiology, ISSN 0008-6312, 11/2017, Volume 138, Issue 3, pp. 164 - 168
Objectives: The PLATO trial revealed superiority of ticagrelor over clopidogrel for the prevention of atherothrombotic events in patients with acute coronary... 
Short Communication
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 07/2018, Volume 11, Issue 14, pp. 1340 - 1350
The purpose of this study was to assess neoatherosclerosis in a registry of prospectively enrolled patients presenting with stent thrombosis using optical... 
imaging | stent thrombosis | neoatherosclerosis
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 07/2018, Volume 11, Issue 14, pp. 1340 - 1350
Objectives: The purpose of this study was to assess neoatherosclerosis in a registry of prospectively enrolled patients presenting with stent thrombosis using... 
imaging | stent thrombosis | neoatherosclerosis | CARDIAC & CARDIOVASCULAR SYSTEMS | IMPLANTATION | PREDICTORS | BARE-METAL | DRUG-ELUTING STENTS
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 12/2017, Volume 10, Issue 24, pp. 2548 - 2556
Objectives High platelet reactivity (HPR) was studied in patients presenting with ST-segment elevation myocardial infarction (STEMI) due to stent thrombosis... 
aspirin | receptor antagonists | P2Y | platelet function tests | stent thrombosis | platelet aggregation | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | MANAGEMENT | RETICULATED PLATELETS | REPERFUSION | IMPAIRED BIOAVAILABILITY | IMPACT | CLOPIDOGREL | INHIBITION | THERAPY | P2Y receptor antagonists | Recurrence | Humans | Middle Aged | Receptors, Purinergic P2Y12 - drug effects | Male | ST Elevation Myocardial Infarction - blood | Adenosine Diphosphate - blood | Coronary Thrombosis - diagnostic imaging | Purinergic P2Y Receptor Antagonists - adverse effects | Percutaneous Coronary Intervention - instrumentation | Receptors, Purinergic P2Y12 - blood | Time Factors | Coronary Thrombosis - prevention & control | Platelet Function Tests | Female | Registries | Blood Platelets - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Coronary Thrombosis - blood | Drug Resistance | Purinergic P2Y Receptor Antagonists - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | ST Elevation Myocardial Infarction - etiology | Europe | Risk Factors | Treatment Outcome | Biomarkers - blood | Blood Platelets - metabolism | ST Elevation Myocardial Infarction - surgery | ST Elevation Myocardial Infarction - diagnostic imaging | Aged | Coronary Thrombosis - etiology | Stents - adverse effects | Percutaneous Coronary Intervention - adverse effects
Journal Article
European journal of clinical pharmacology, 06/2019
The POPular Risk Score was developed for the selective intensification of P2Y inhibitor treatment with prasugrel instead of clopidogrel in patients undergoing... 
Journal Article